10X GENOMICS INC-CLASS A (TXG) Stock Overview
NASDAQ:TXG - US88025U1097 - Common Stock
TXG Key Statistics, Chart & Performance
The current stock price of TXG is 14.01 USD. In the past month the price increased by 7.11%. In the past year, price decreased by -40%.
TXG Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 22.51 | 186.06B | ||
| DHR | DANAHER CORP | 27.33 | 147.38B | ||
| A | AGILENT TECHNOLOGIES INC | 23.06 | 35.69B | ||
| IQV | IQVIA HOLDINGS INC | 16.64 | 32.44B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 31.81 | 26.80B | ||
| WAT | WATERS CORP | 24.68 | 17.96B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 35.48 | 17.76B | ||
| ILMN | ILLUMINA INC | 24.03 | 15.36B | ||
| ICLR | ICON PLC | 13.45 | 13.84B | ||
| MEDP | MEDPACE HOLDINGS INC | 35.35 | 13.36B | ||
| TEM | TEMPUS AI INC | N/A | 13.18B | ||
| RVTY | REVVITY INC | 18.43 | 10.46B |
Related stock screener links
About TXG
Company Profile
10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. The company is headquartered in Pleasanton, California and currently employs 1,306 full-time employees. The company went IPO on 2019-09-12. The firm's integrated solutions include instruments, consumables and software for single cell and spatial biology systems. Its single cell portfolio, powered by Chromium platform, includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Visium Spatial Gene Expression, and others.
Company Info
10X GENOMICS INC-CLASS A
6230 Stoneridge Mall Road
Pleasanton CALIFORNIA 94588 US
CEO: Serge Saxonov
Employees: 1306
Phone: 19254017300
10X GENOMICS INC-CLASS A / TXG FAQ
What is the stock price of 10X GENOMICS INC-CLASS A today?
The current stock price of TXG is 14.01 USD. The price decreased by -1.89% in the last trading session.
What is the ticker symbol for 10X GENOMICS INC-CLASS A stock?
The exchange symbol of 10X GENOMICS INC-CLASS A is TXG and it is listed on the Nasdaq exchange.
On which exchange is TXG stock listed?
TXG stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for 10X GENOMICS INC-CLASS A stock?
22 analysts have analysed TXG and the average price target is 15.3 USD. This implies a price increase of 9.21% is expected in the next year compared to the current price of 14.01. Check the 10X GENOMICS INC-CLASS A stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is 10X GENOMICS INC-CLASS A worth?
10X GENOMICS INC-CLASS A (TXG) has a market capitalization of 1.74B USD. This makes TXG a Small Cap stock.
How many employees does 10X GENOMICS INC-CLASS A have?
10X GENOMICS INC-CLASS A (TXG) currently has 1306 employees.
What are the support and resistance levels for 10X GENOMICS INC-CLASS A (TXG) stock?
10X GENOMICS INC-CLASS A (TXG) has a support level at 13.48 and a resistance level at 14.31. Check the full technical report for a detailed analysis of TXG support and resistance levels.
Is 10X GENOMICS INC-CLASS A (TXG) expected to grow?
The Revenue of 10X GENOMICS INC-CLASS A (TXG) is expected to grow by 1.66% in the next year. Check the estimates tab for more information on the TXG EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy 10X GENOMICS INC-CLASS A (TXG) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of TXG, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of TXG, evaluating the profitability, health, valuation and growth aspects
- 10X GENOMICS INC-CLASS A (TXG) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- 10X GENOMICS INC-CLASS A (TXG) Sales and EPS estimates to see what analysts future expectations are.
- 10X GENOMICS INC-CLASS A (TXG) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- 10X GENOMICS INC-CLASS A (TXG) Insider and Institutional Ownership to learn about the owners and their transactions.
- 10X GENOMICS INC-CLASS A (TXG) Stock Chart to make your own analysis
- 10X GENOMICS INC-CLASS A (TXG) Latest news and press-releases to stay up to date.
Does 10X GENOMICS INC-CLASS A (TXG) stock pay dividends?
TXG does not pay a dividend.
When does 10X GENOMICS INC-CLASS A (TXG) report earnings?
10X GENOMICS INC-CLASS A (TXG) will report earnings on 2025-10-27, after the market close.
What is the Price/Earnings (PE) ratio of 10X GENOMICS INC-CLASS A (TXG)?
10X GENOMICS INC-CLASS A (TXG) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.78).
What is the Short Interest ratio of 10X GENOMICS INC-CLASS A (TXG) stock?
The outstanding short interest for 10X GENOMICS INC-CLASS A (TXG) is 13.27% of its float. Check the ownership tab for more information on the TXG short interest.
TXG Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to TXG. When comparing the yearly performance of all stocks, TXG turns out to be only a medium performer in the overall market: it outperformed 46.91% of all stocks.
TXG Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to TXG. No worries on liquidiy or solvency for TXG as it has an excellent financial health rating, but there are worries on the profitability.
TXG Financial Highlights
Over the last trailing twelve months TXG reported a non-GAAP Earnings per Share(EPS) of -0.78. The EPS increased by 61.39% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -8.63% | ||
| ROE | -10.94% | ||
| Debt/Equity | 0 |
TXG Forecast & Estimates
22 analysts have analysed TXG and the average price target is 15.3 USD. This implies a price increase of 9.21% is expected in the next year compared to the current price of 14.01.
For the next year, analysts expect an EPS growth of 55.3% and a revenue growth 1.66% for TXG